A brand's product card is designed for a medical representative to leave with a doctor. Then it gets a second life. Someone photographs it and forwards it on WhatsApp, and from there it travels into a patient group or onto a social feed. The card is the same as it was. Only the audience is different, and a different audience brings a different law.
Two Different Audiences, Two Different Rules
In law, a visual aid or a leave behind for a doctor is a communication to a registered medical practitioner. A poster a patient reads, or an image circulating on a phone, is an advertisement to the public. The two sit under very different rules, and the gap between them is wider than most brand teams assume.
Prescription Drugs and the Public
Prescription medicines are not advertised to the public in India. The Drugs and Cosmetics Rules require the prior sanction of the central government before a drug listed under Schedule H, H1 or X is advertised at all. Schedule H is the prescription list. Schedule H1 covers the higher-risk drugs, many antibiotics and psychotropics. Schedule X covers the narcotics and the most controlled. For practical purposes, direct-to-consumer advertising of these drugs is not permitted, and a great deal of pharma collateral is for exactly these drugs.
The Drugs and Magic Remedies Act adds its layer. It bars misleading claims about any drug, and its Schedule prohibits advertising a drug as a cure for a long list of conditions. A claim that was already weak in a doctor's chamber, an absolute, an unreferenced promise, becomes a clear breach the moment it reaches the public. The Consumer Protection framework adds one more. The Central Consumer Protection Authority can order a misleading advertisement modified or withdrawn and impose a penalty, and where a misleading advertisement is found to harm consumers, the law allows for a fine and even imprisonment.
Where the Line Gets Crossed
So the same piece can be lawful in a doctor's chamber and unlawful once it reaches the public. The risk usually comes from a doctor-facing piece that drifts into public view, on a forward or a social post, carrying claims that were only ever cleared for a doctor's eyes. Few brand teams set out to advertise a prescription drug to patients. The breach is usually accidental.
Designing for the Line
For the brand manager, the useful question to ask of every collateral is what happens to it once it leaves the doctor's hands. A piece built for the chamber should be built so it does not invite a wider audience. A piece genuinely meant for patients has to clear an entirely different and higher bar, and it should be treated as a separate project from the start.
Nothing on the page warns that the line has been crossed. The brand team that knows where the line sits can plan for it, keeping the strong, specific claims for the materials that stay with the doctor.
Disclaimer: This is a practitioner reading of the laws for brand teams, not legal advice. The final compliance call sits with your medical and regulatory team.